25 XP   0   0   10

Biocartis Group NV
Buy, Hold or Sell?

Let's analyze Biocartis Group NV together

I guess you are interested in Biocartis Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biocartis Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Biocartis Group NV

I send you an email if I find something interesting about Biocartis Group NV.

Quick analysis of Biocartis Group NV (30 sec.)










What can you expect buying and holding a share of Biocartis Group NV? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨-0.32
Expected worth in 1 year
‚ā¨-0.17
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨0.15
Return On Investment
53.1%

For what price can you sell your share?

Current Price per Share
‚ā¨0.29
Expected price per share
‚ā¨0.287 - ‚ā¨0.293
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Biocartis Group NV (5 min.)




Live pricePrice per Share (EOD)

‚ā¨0.29

Intrinsic Value Per Share

‚ā¨-4.23 - ‚ā¨-2.86

Total Value Per Share

‚ā¨-4.55 - ‚ā¨-3.18

2. Growth of Biocartis Group NV (5 min.)




Is Biocartis Group NV growing?

Current yearPrevious yearGrowGrow %
How rich?-$33m-$36.9m$3.9m11.9%

How much money is Biocartis Group NV making?

Current yearPrevious yearGrowGrow %
Making money-$71.3m-$77.9m$6.6m9.3%
Net Profit Margin-113.7%-148.1%--

How much money comes from the company's main activities?

3. Financial Health of Biocartis Group NV (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#139 / 141

Most Revenue
#61 / 141

Most Profit
#136 / 141

Most Efficient
#108 / 141
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Biocartis Group NV? (5 min.)

Welcome investor! Biocartis Group NV's management wants to use your money to grow the business. In return you get a share of Biocartis Group NV.

What can you expect buying and holding a share of Biocartis Group NV?

First you should know what it really means to hold a share of Biocartis Group NV. And how you can make/lose money.

Speculation

The Price per Share of Biocartis Group NV is ‚ā¨0.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biocartis Group NV.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biocartis Group NV, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨-0.32. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.04 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨-0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biocartis Group NV.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-0.55-191.0%-0.55-191.0%-0.83-286.3%-0.68-235.8%-0.55-188.5%
Usd Book Value Change Per Share0.0414.5%0.0414.5%-0.82-283.3%-0.38-130.2%-0.08-26.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.0414.5%0.0414.5%-0.82-283.3%-0.38-130.2%-0.08-26.9%
Usd Price Per Share0.58-0.58-3.94-5.34-6.61-
Price to Earnings Ratio-1.04--1.04--4.75--8.10--11.91-
Price-to-Total Gains Ratio13.72-13.72--4.80--41.62--27.55-
Price to Book Ratio-1.64--1.64--10.02-3.45-4.72-
Price-to-Total Gains Ratio13.72-13.72--4.80--41.62--27.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.31639
Number of shares3160
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.04-0.38
Usd Total Gains Per Share0.04-0.38
Gains per Quarter (3160 shares)132.63-1,193.21
Gains per Year (3160 shares)530.52-4,772.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105315210-4773-4783
20106110520-9546-9556
30159215830-14319-14329
40212221140-19091-19102
50265326450-23864-23875
60318331760-28637-28648
70371437070-33410-33421
80424442380-38183-38194
90477547690-42956-42967
100530553000-47728-47740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%4.07.00.036.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%4.07.00.036.4%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Biocartis Group NV

About Biocartis Group NV

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Fundamental data was last updated by Penke on 2024-07-07 23:18:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Biocartis Group NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Biocartis Group NV earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • A Net Profit Margin of -113.7%¬†means that¬†€-1.14 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biocartis Group NV:

  • The MRQ is -113.7%. The company is making a huge loss. -2
  • The TTM is -113.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-113.7%TTM-113.7%0.0%
TTM-113.7%YOY-148.1%+34.3%
TTM-113.7%5Y-150.4%+36.7%
5Y-150.4%10Y-219.7%+69.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-113.7%-9.4%-104.3%
TTM-113.7%-11.3%-102.4%
YOY-148.1%-3.6%-144.5%
5Y-150.4%-2.2%-148.2%
10Y-219.7%-0.5%-219.2%
1.1.2. Return on Assets

Shows how efficient Biocartis Group NV is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • -57.2% Return on Assets means that¬†Biocartis Group NV generated¬†€-0.57 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biocartis Group NV:

  • The MRQ is -57.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -57.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-57.2%TTM-57.2%0.0%
TTM-57.2%YOY-50.2%-7.0%
TTM-57.2%5Y-39.1%-18.1%
5Y-39.1%10Y-35.7%-3.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-57.2%-2.3%-54.9%
TTM-57.2%-2.0%-55.2%
YOY-50.2%-0.6%-49.6%
5Y-39.1%-0.3%-38.8%
10Y-35.7%-0.3%-35.4%
1.1.3. Return on Equity

Shows how efficient Biocartis Group NV is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • 0.0% Return on Equity means Biocartis Group NV generated €0.00¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biocartis Group NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-60.4%+60.4%
5Y-60.4%10Y-57.6%-2.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--0.7%+0.7%
TTM--1.9%+1.9%
YOY--0.3%+0.3%
5Y-60.4%-0.9%-59.5%
10Y-57.6%-1.5%-56.1%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Biocartis Group NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biocartis Group NV is operating .

  • Measures how much profit Biocartis Group NV makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • An Operating Margin of -81.3%¬†means the company generated €-0.81 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biocartis Group NV:

  • The MRQ is -81.3%. The company is operating very inefficient. -2
  • The TTM is -81.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-81.3%TTM-81.3%0.0%
TTM-81.3%YOY-129.1%+47.7%
TTM-81.3%5Y-126.8%+45.5%
5Y-126.8%10Y-222.0%+95.2%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-81.3%-17.0%-64.3%
TTM-81.3%-9.5%-71.8%
YOY-129.1%1.6%-130.7%
5Y-126.8%2.0%-128.8%
10Y-222.0%3.5%-225.5%
1.2.2. Operating Ratio

Measures how efficient Biocartis Group NV is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Diagnostics & Research industry mean).
  • An Operation Ratio of 1.81 means that the operating costs are €1.81 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biocartis Group NV:

  • The MRQ is 1.813. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.813. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.813TTM1.8130.000
TTM1.813YOY2.291-0.477
TTM1.8135Y2.268-0.455
5Y2.26810Y3.215-0.947
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8131.369+0.444
TTM1.8131.327+0.486
YOY2.2911.263+1.028
5Y2.2681.245+1.023
10Y3.2151.155+2.060
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Biocartis Group NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biocartis Group NV is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Diagnostics & Research industry mean).
  • A Current Ratio of 1.65¬†means the company has €1.65 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biocartis Group NV:

  • The MRQ is 1.647. The company is able to pay all its short-term debts. +1
  • The TTM is 1.647. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.647TTM1.6470.000
TTM1.647YOY2.822-1.175
TTM1.6475Y4.728-3.081
5Y4.72810Y4.820-0.092
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6472.031-0.384
TTM1.6472.238-0.591
YOY2.8222.568+0.254
5Y4.7282.830+1.898
10Y4.8202.925+1.895
1.3.2. Quick Ratio

Measures if Biocartis Group NV is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • A Quick Ratio of 1.20¬†means the company can pay off €1.20 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biocartis Group NV:

  • The MRQ is 1.202. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.202. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.202TTM1.2020.000
TTM1.202YOY2.344-1.142
TTM1.2025Y4.107-2.905
5Y4.10710Y4.263-0.156
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2021.202+0.000
TTM1.2021.247-0.045
YOY2.3441.617+0.727
5Y4.1071.929+2.178
10Y4.2632.234+2.029
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Biocartis Group NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biocartis Group NV assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Biocartis Group NV to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 1.27¬†means that Biocartis Group NV assets are¬†financed with 126.5% credit (debt) and the remaining percentage (100% - 126.5%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Biocartis Group NV:

  • The MRQ is 1.265. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.265. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.265TTM1.2650.000
TTM1.265YOY1.238+0.027
TTM1.2655Y0.877+0.388
5Y0.87710Y0.628+0.249
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2650.429+0.836
TTM1.2650.390+0.875
YOY1.2380.367+0.871
5Y0.8770.424+0.453
10Y0.6280.442+0.186
1.4.2. Debt to Equity Ratio

Measures if Biocartis Group NV is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biocartis Group NV:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.498-1.498
5Y1.49810Y1.110+0.387
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.613-0.613
TTM-0.570-0.570
YOY-0.478-0.478
5Y1.4980.639+0.859
10Y1.1100.706+0.404
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Biocartis Group NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Biocartis Group NV generates.

  • Above 15 is considered overpriced but¬†always compare¬†Biocartis Group NV to the¬†Diagnostics & Research industry mean.
  • A PE ratio of -1.04 means the investor is paying €-1.04¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biocartis Group NV:

  • The EOD is -0.571. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.040. Based on the earnings, the company is expensive. -2
  • The TTM is -1.040. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.571MRQ-1.040+0.469
MRQ-1.040TTM-1.0400.000
TTM-1.040YOY-4.750+3.710
TTM-1.0405Y-8.100+7.060
5Y-8.10010Y-11.909+3.809
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.571-0.356-0.215
MRQ-1.040-0.857-0.183
TTM-1.040-0.500-0.540
YOY-4.750-0.085-4.665
5Y-8.1002.211-10.311
10Y-11.9093.497-15.406
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biocartis Group NV:

  • The EOD is -0.582. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.060. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.060. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.582MRQ-1.060+0.478
MRQ-1.060TTM-1.0600.000
TTM-1.060YOY-4.887+3.827
TTM-1.0605Y-9.052+7.992
5Y-9.05210Y-12.341+3.290
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.582-0.919+0.337
MRQ-1.060-1.362+0.302
TTM-1.060-1.242+0.182
YOY-4.887-2.859-2.028
5Y-9.052-0.591-8.461
10Y-12.341-2.357-9.984
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biocartis Group NV is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Diagnostics & Research industry mean).
  • A PB ratio of -1.64 means the investor is paying €-1.64¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biocartis Group NV:

  • The EOD is -0.899. Based on the equity, the company is expensive. -2
  • The MRQ is -1.637. Based on the equity, the company is expensive. -2
  • The TTM is -1.637. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.899MRQ-1.637+0.738
MRQ-1.637TTM-1.6370.000
TTM-1.637YOY-10.016+8.378
TTM-1.6375Y3.450-5.088
5Y3.45010Y4.716-1.265
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.8991.870-2.769
MRQ-1.6372.157-3.794
TTM-1.6372.190-3.827
YOY-10.0162.787-12.803
5Y3.4503.884-0.434
10Y4.7164.469+0.247
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Biocartis Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0380.0380%-0.753+2057%-0.346+1000%-0.071+286%
Book Value Per Share---0.322-0.3220%-0.361+12%0.308-205%0.576-156%
Current Ratio--1.6471.6470%2.822-42%4.728-65%4.820-66%
Debt To Asset Ratio--1.2651.2650%1.238+2%0.877+44%0.628+101%
Debt To Equity Ratio----0%-0%1.498-100%1.110-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.508-0.5080%-0.761+50%-0.627+23%-0.501-1%
Free Cash Flow Per Share---0.498-0.4980%-0.740+48%-0.560+12%-0.521+5%
Free Cash Flow To Equity Per Share---0.259-0.2590%-0.753+190%-0.170-34%-0.018-93%
Gross Profit Margin--1.0771.0770%1.043+3%1.069+1%1.0780%
Intrinsic Value_10Y_max---2.860--------
Intrinsic Value_10Y_min---4.226--------
Intrinsic Value_1Y_max---0.472--------
Intrinsic Value_1Y_min---0.533--------
Intrinsic Value_3Y_max---1.276--------
Intrinsic Value_3Y_min---1.516--------
Intrinsic Value_5Y_max---1.911--------
Intrinsic Value_5Y_min---2.398--------
Market Cap27235612.160-82%49587597.31249587597.3120%339505992.960-85%459305120.102-89%568829847.347-91%
Net Profit Margin---1.137-1.1370%-1.481+30%-1.504+32%-2.197+93%
Operating Margin---0.813-0.8130%-1.291+59%-1.268+56%-2.220+173%
Operating Ratio--1.8131.8130%2.291-21%2.268-20%3.215-44%
Pb Ratio-0.899+45%-1.637-1.6370%-10.016+512%3.450-147%4.716-135%
Pe Ratio-0.571+45%-1.040-1.0400%-4.750+357%-8.100+679%-11.909+1045%
Price Per Share0.290-82%0.5280.5280%3.615-85%4.891-89%6.057-91%
Price To Free Cash Flow Ratio-0.582+45%-1.060-1.0600%-4.887+361%-9.052+754%-12.341+1065%
Price To Total Gains Ratio7.538-82%13.72513.7250%-4.801+135%-41.617+403%-27.547+301%
Quick Ratio--1.2021.2020%2.344-49%4.107-71%4.263-72%
Return On Assets---0.572-0.5720%-0.502-12%-0.391-32%-0.357-38%
Return On Equity----0%-0%-0.6040%-0.5760%
Total Gains Per Share--0.0380.0380%-0.753+2057%-0.346+1000%-0.071+286%
Usd Book Value---33039844.000-33039844.0000%-36981627.000+12%31524008.600-205%58996043.200-156%
Usd Book Value Change Per Share--0.0420.0420%-0.822+2057%-0.378+1000%-0.078+286%
Usd Book Value Per Share---0.352-0.3520%-0.394+12%0.336-205%0.628-156%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.554-0.5540%-0.830+50%-0.684+23%-0.547-1%
Usd Free Cash Flow---51050072.000-51050072.0000%-75792861.000+48%-57417148.000+12%-53423433.400+5%
Usd Free Cash Flow Per Share---0.544-0.5440%-0.807+48%-0.611+12%-0.569+5%
Usd Free Cash Flow To Equity Per Share---0.283-0.2830%-0.821+190%-0.186-34%-0.020-93%
Usd Market Cap29714052.867-82%54100068.66754100068.6670%370401038.319-85%501101886.032-89%620593363.456-91%
Usd Price Per Share0.316-82%0.5760.5760%3.944-85%5.336-89%6.608-91%
Usd Profit---71330671.000-71330671.0000%-77975952.000+9%-68080145.600-5%-53271348.000-25%
Usd Revenue--62711771.00062711771.0000%52661479.000+19%46723820.600+34%30256812.100+107%
Usd Total Gains Per Share--0.0420.0420%-0.822+2057%-0.378+1000%-0.078+286%
 EOD+1 -7MRQTTM+0 -0YOY+22 -105Y+18 -1510Y+15 -18

3.2. Fundamental Score

Let's check the fundamental score of Biocartis Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.571
Price to Book Ratio (EOD)Between0-1-0.899
Net Profit Margin (MRQ)Greater than0-1.137
Operating Margin (MRQ)Greater than0-0.813
Quick Ratio (MRQ)Greater than11.202
Current Ratio (MRQ)Greater than11.647
Debt to Asset Ratio (MRQ)Less than11.265
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.572
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Biocartis Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.290
Ma 50Greater thanMa 1000.290
Ma 100Greater thanMa 2000.290
OpenGreater thanClose0.290
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets114,277
Total Liabilities144,561
Total Stockholder Equity-30,284
 As reported
Total Liabilities 144,561
Total Stockholder Equity+ -30,284
Total Assets = 114,277

Assets

Total Assets114,277
Total Current Assets69,934
Long-term Assets44,343
Total Current Assets
Cash And Cash Equivalents 24,925
Net Receivables 26,103
Inventory 18,905
Other Current Assets 1
Total Current Assets  (as reported)69,934
Total Current Assets  (calculated)69,934
+/-0
Long-term Assets
Property Plant Equipment 31,527
Intangible Assets 4,769
Other Assets 5,508
Long-term Assets  (as reported)44,343
Long-term Assets  (calculated)41,804
+/- 2,539

Liabilities & Shareholders' Equity

Total Current Liabilities42,449
Long-term Liabilities102,112
Total Stockholder Equity-30,284
Total Current Liabilities
Short-term Debt 20,597
Short Long Term Debt 15,000
Accounts payable 11,747
Other Current Liabilities 8,910
Total Current Liabilities  (as reported)42,449
Total Current Liabilities  (calculated)56,254
+/- 13,805
Long-term Liabilities
Long term Debt 92,707
Capital Lease Obligations 14,648
Other Liabilities 353
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)102,112
Long-term Liabilities  (calculated)107,709
+/- 5,597
Total Stockholder Equity
Common Stock931
Retained Earnings -443,363
Accumulated Other Comprehensive Income -219,573
Other Stockholders Equity 631,721
Total Stockholder Equity (as reported)-30,284
Total Stockholder Equity (calculated)-30,284
+/-0
Other
Capital Stock-220,302
Cash and Short Term Investments 24,925
Common Stock Shares Outstanding 60,546
Current Deferred Revenue1,195
Liabilities and Stockholders Equity 114,277
Net Debt 97,430
Net Invested Capital 77,423
Net Tangible Assets -30,501
Net Working Capital 27,485
Property Plant and Equipment Gross 81,588
Short Long Term Debt Total 122,355



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
66,188
60,145
53,012
148,378
141,305
181,191
139,385
268,323
210,517
142,480
114,277
114,277142,480210,517268,323139,385181,191141,305148,37853,01260,14566,188
   > Total Current Assets 
44,810
38,609
33,142
118,097
100,143
133,090
90,783
214,628
159,983
95,126
69,934
69,93495,126159,983214,62890,783133,090100,143118,09733,14238,60944,810
       Cash And Cash Equivalents 
40,494
27,047
9,419
102,587
82,046
111,565
62,339
177,525
122,468
52,322
24,925
24,92552,322122,468177,52562,339111,56582,046102,5879,41927,04740,494
       Net Receivables 
3,845
7,924
20,142
9,674
5,911
6,892
9,744
22,943
18,910
26,697
26,103
26,10326,69718,91022,9439,7446,8925,9119,67420,1427,9243,845
       Inventory 
183
1,116
3,583
5,837
9,829
9,060
11,919
14,161
15,712
16,106
18,905
18,90516,10615,71214,16111,9199,0609,8295,8373,5831,116183
   > Long-term Assets 
21,378
21,536
19,870
30,281
41,162
48,102
48,602
53,695
50,534
47,354
44,343
44,34347,35450,53453,69548,60248,10241,16230,28119,87021,53621,378
       Property Plant Equipment 
10,994
11,199
9,154
14,245
23,088
26,199
30,391
43,421
40,098
37,192
31,527
31,52737,19240,09843,42130,39126,19923,08814,2459,15411,19910,994
       Long Term Investments 
0
245
0
5,052
5,052
5,052
5,052
2,358
0
0
0
0002,3585,0525,0525,0525,05202450
       Intangible Assets 
10,278
9,985
9,652
8,988
9,922
10,268
6,579
6,294
5,645
5,066
4,769
4,7695,0665,6456,2946,57910,2689,9228,9889,6529,98510,278
       Other Assets 
106
107
1,064
1,986
3,101
-1
6,580
1,622
1,898
2,751
5,508
5,5082,7511,8981,6226,580-13,1011,9861,064107106
> Total Liabilities 
29,388
28,190
32,732
33,462
44,416
48,952
52,034
183,844
173,693
176,377
144,561
144,561176,377173,693183,84452,03448,95244,41633,46232,73228,19029,388
   > Total Current Liabilities 
11,781
11,649
17,714
27,877
14,908
15,800
20,278
23,176
29,445
33,705
42,449
42,44933,70529,44523,17620,27815,80014,90827,87717,71411,64911,781
       Short-term Debt 
1,250
3,373
5,056
8,152
3,699
4,029
5,114
6,420
6,673
11,878
20,597
20,59711,8786,6736,4205,1144,0293,6998,1525,0563,3731,250
       Short Long Term Debt 
0
16,195
3,895
7,234
118
120
1,324
125
58
6,000
15,000
15,0006,000581251,3241201187,2343,89516,1950
       Accounts payable 
8,454
5,847
4,265
13,927
6,293
5,555
7,973
9,070
13,907
11,560
11,747
11,74711,56013,9079,0707,9735,5556,29313,9274,2655,8478,454
       Other Current Liabilities 
44
614
95
102
592
6,216
7,191
6,091
41
43
8,910
8,91043416,0917,1916,2165921029561444
   > Long-term Liabilities 
17,607
16,541
15,018
5,585
29,508
33,152
31,756
160,668
144,248
142,672
102,112
102,112142,672144,248160,66831,75633,15229,5085,58515,01816,54117,607
       Long term Debt Total 
0
0
0
2,662
27,709
31,359
30,221
160,158
0
0
0
000160,15830,22131,35927,7092,662000
       Long term Debt 
10,089
12,822
8,528
542
15,688
16,636
16,454
136,216
125,260
128,151
92,707
92,707128,151125,260136,21616,45416,63615,6885428,52812,82210,089
       Capital Lease Obligations 
0
0
0
0
15,603
18,632
17,557
30,237
25,240
20,011
14,648
14,64820,01125,24030,23717,55718,63215,6030000
       Other Liabilities 
7,518
3,719
6,489
2,923
1,799
1,793
1,535
510
363
388
353
3533883635101,5351,7931,7992,9236,4893,7197,518
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
1
10000000000
> Total Stockholder Equity
36,800
31,955
20,280
114,916
96,889
132,239
87,351
84,479
36,824
-33,897
-30,284
-30,284-33,89736,82484,47987,351132,23996,889114,91620,28031,95536,800
   Common Stock
795
926
1,036
-220,827
-220,786
-220,721
-220,718
565
575
575
931
931575575565-220,718-220,721-220,786-220,8271,036926795
   Retained Earnings -443,363-526,405-455,343-397,550-328,145-280,046-238,088-188,310-148,513-145,631-110,010
   Accumulated Other Comprehensive Income -219,573-219,942-220,282-221,854-24,067-20,492-16,210-12,424-8,498-5,366-2,433
   Capital Surplus 
0
0
0
522,708
554,065
630,670
632,769
698,027
0
0
0
000698,027632,769630,670554,065522,708000
   Treasury Stock00000000000
   Other Stockholders Equity 
148,448
182,026
176,255
536,477
571,973
653,498
439,563
482,029
711,874
711,875
631,721
631,721711,875711,874482,029439,563653,498571,973536,477176,255182,026148,448



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue57,481
Cost of Revenue-29,799
Gross Profit27,68227,682
 
Operating Income (+$)
Gross Profit27,682
Operating Expense-74,433
Operating Income-46,751-46,751
 
Operating Expense (+$)
Research Development38,393
Selling General Administrative3,524
Selling And Marketing Expenses5,049
Operating Expense74,43346,966
 
Net Interest Income (+$)
Interest Income0
Interest Expense-11,187
Other Finance Cost-6,503
Net Interest Income-17,690
 
Pretax Income (+$)
Operating Income-46,751
Net Interest Income-17,690
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-65,621-27,881
EBIT - interestExpense = -57,938
-65,621
-54,194
Interest Expense11,187
Earnings Before Interest and Taxes (EBIT)-46,751-54,434
Earnings Before Interest and Taxes (EBITDA)-43,659
 
After tax Income (+$)
Income Before Tax-65,621
Tax Provision--240
Net Income From Continuing Ops-65,381-65,381
Net Income-65,381
Net Income Applicable To Common Shares-47,681
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses104,232
Total Other Income/Expenses Net-18,87017,690
 

Technical Analysis of Biocartis Group NV
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biocartis Group NV. The general trend of Biocartis Group NV is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biocartis Group NV's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biocartis Group NV.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.293 < 0.293 < 0.293.

The bearish price targets are: 0.287 > 0.287 > 0.287.

Tweet this
Biocartis Group NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biocartis Group NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biocartis Group NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biocartis Group NV. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biocartis Group NV price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biocartis Group NV. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biocartis Group NV price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Biocartis Group NV Daily Moving Average Convergence/Divergence (MACD) ChartBiocartis Group NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biocartis Group NV. The current adx is 20.24.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biocartis Group NV shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Biocartis Group NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biocartis Group NV. The current sar is 0.287.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Biocartis Group NV Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biocartis Group NV. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Biocartis Group NV Daily Relative Strength Index (RSI) ChartBiocartis Group NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biocartis Group NV. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -3/(-6 +6).

  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biocartis Group NV price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Biocartis Group NV Daily Stochastic Oscillator ChartBiocartis Group NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biocartis Group NV. The current cci is 0.

Biocartis Group NV Daily Commodity Channel Index (CCI) ChartBiocartis Group NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biocartis Group NV. The current cmo is 0.

Biocartis Group NV Daily Chande Momentum Oscillator (CMO) ChartBiocartis Group NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biocartis Group NV. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biocartis Group NV is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Biocartis Group NV Daily Williams %R ChartBiocartis Group NV Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of Biocartis Group NV.

Biocartis Group NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biocartis Group NV. The current atr is 0.006.

Biocartis Group NV Daily Average True Range (ATR) ChartBiocartis Group NV Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biocartis Group NV. The current obv is -13,488,584.

Biocartis Group NV Daily On-Balance Volume (OBV) ChartBiocartis Group NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biocartis Group NV. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Biocartis Group NV Daily Money Flow Index (MFI) ChartBiocartis Group NV Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biocartis Group NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside